Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of DirectorsRead More
Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor ConferenceRead More
Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical IndicationsRead More
Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002Read More